1.82
-0.08 (-4.21%)
| Previous Close | 1.90 |
| Volume | 2,972,646 |
| Price / Sales | 269.28 |
| Price / Book | 2.06 |
| 52 Weeks Range |
| Operating Margin (TTM) | -7,273.06% |
| Diluted EPS (TTM) | -0.400 |
| Total Debt/Equity (MRQ) | 5.79% |
| Current Ratio (MRQ) | 8.33 |
| Operating Cash Flow (TTM) | -44.17 M |
| Levered Free Cash Flow (TTM) | -25.01 M |
| Return on Assets (TTM) | -26.41% |
| Return on Equity (TTM) | -41.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Compass Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 14.16% |
| % Held by Institutions | 67.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Enavate Sciences Gp, Llc | 30 Jun 2026 | 7,788,150 |
| Vivo Capital, Llc | 30 Jun 2026 | 7,757,060 |
| Palo Alto Investors Lp | 30 Jun 2026 | 5,831,813 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 3,624,076 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |